|Articles|June 1, 2002
Latanoprost plus brimonidine controls IOP
Austin, TX-Patients who need more than one ocular hypotensive agent to achieve low IOP may benefit more from a regimen of latanoprost (Xalatan, Pharmacia) and adjunctive brimonidine (Alphagan, Allergan) than from dual therapy with latanoprost and timolol, according to a recent study.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Study identifies corneal endothelial changes following mRNA COVID-19 vaccination
2
SpyGlass Pharma randomizes first patients in 2 phase 3 clinical trials of the BIM-IOL System
3
Moorfields study reveals sharp rise in glaucoma burden across the UK
4
Q&A: Evolving approaches to geographic atrophy management
5










































